337 related articles for article (PubMed ID: 15478467)
1. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
2. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
3. Antibody therapy for familial amyloidotic polyneuropathy.
Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915
[TBL] [Abstract][Full Text] [Related]
4. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.
Teixeira AC; Saraiva MJ
J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326
[TBL] [Abstract][Full Text] [Related]
5. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
6. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
7. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
8. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
9. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.
Ueda M; Ando Y; Hakamata Y; Nakamura M; Yamashita T; Obayashi K; Himeno S; Inoue S; Sato Y; Kaneko T; Takamune N; Misumi S; Shoji S; Uchino M; Kobayashi E
Biochem Biophys Res Commun; 2007 Jan; 352(2):299-304. PubMed ID: 17126291
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
Ferreira N; Saraiva MJ; Almeida MR
PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829
[TBL] [Abstract][Full Text] [Related]
11. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
12. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.
Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ
Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349
[TBL] [Abstract][Full Text] [Related]
13. Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy.
Kugimiya T; Jono H; Saito S; Maruyama T; Kadowaki D; Misumi Y; Hoshii Y; Tasaki M; Su Y; Ueda M; Obayashi K; Shono M; Otagiri M; Ando Y
Lab Invest; 2011 Aug; 91(8):1219-28. PubMed ID: 21537325
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ
Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model.
Batista AR; Gianni D; Ventosa M; Coelho AV; Almeida MR; Sena-Esteves M; Saraiva MJ
Gene Ther; 2014 Dec; 21(12):1041-50. PubMed ID: 25273354
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
Ando Y
Med Mol Morphol; 2005 Sep; 38(3):142-54. PubMed ID: 16170462
[TBL] [Abstract][Full Text] [Related]
17. The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model.
Gonçalves NP; Teixeira-Coelho M; Saraiva MJ
Exp Neurol; 2014 Jul; 257():76-87. PubMed ID: 24800914
[TBL] [Abstract][Full Text] [Related]
18. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiological parameters that contribute to the pathogenesis of familial amyloid polyneuropathy caused by transthyretin mutations.
Lai HJ; Lai WT; Jin L; Kuo KT; Lee MJ
J Neurol Sci; 2020 Jun; 413():116810. PubMed ID: 32247966
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin deposition in familial amyloidotic polyneuropathy.
Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
